Abstract
Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
Keywords: COVID-19; Kaletra; adverse reactions; chloroquine; drug-drug interaction; remdesivir.
All Keywords
【저자키워드】 COVID-19, Chloroquine, remdesivir., Adverse reactions, Kaletra, drug-drug interaction, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Chloroquine, Lopinavir/ritonavir, Tocilizumab, Lopinavir, Ritonavir, Infection, drugs, Remdesivir, risk, medications, ribavirin, Adverse reactions, Patient, medication, Kaletra, drug-drug interaction, hepatotoxicity, Interaction, retinopathy, increased risk, Serious adverse reactions, concomitant use, occurred, occur, serious adverse reaction, 【제목키워드】 medication, Interaction,
【저자키워드】 COVID-19, Chloroquine, remdesivir., Adverse reactions, Kaletra, drug-drug interaction, 【초록키워드】 Treatment, coronavirus disease, Coronavirus disease 2019, Chloroquine, Lopinavir/ritonavir, Tocilizumab, Lopinavir, Ritonavir, Infection, drugs, Remdesivir, risk, medications, ribavirin, Adverse reactions, Patient, medication, Kaletra, drug-drug interaction, hepatotoxicity, Interaction, retinopathy, increased risk, Serious adverse reactions, concomitant use, occurred, occur, serious adverse reaction, 【제목키워드】 medication, Interaction,
{{{ 추상적인 }}}
DDI(Drug-Drug Interaction)는 여러 약물의 병용 사용으로 인해 발생하는 일반적인 임상 문제입니다. DDI는 코로나바이러스 2019(COVID-19)에 사용되는 약물(예: 클로로퀸, 로피나비르/리토나비르, 리바비린, 토실리주맙, 렘데시비르)로 치료 중인 환자에서 발생할 수 있으며 QT 연장, 망막병증, 감염 위험 증가, 간독성. 이 검토는 부작용을 최소화하기 위해 COVID-19에 사용되는 후보 약물에 대한 DDI 요약에 중점을 둡니다.
{{ 키워드: }} 코로나19; 칼레트라; 이상 반응; 클로로퀸; 약물-약물 상호작용; 렘데시비르.